Artificial Intelligence Enhances Speed and Precision in Autism and ADHD Diagnosis

Innovative AI techniques are accelerating and improving the accuracy of autism and ADHD diagnoses through quantitative biomarker analysis, enabling faster assessments and personalized treatment planning.
Recent advancements in artificial intelligence (AI) are revolutionizing the diagnosis process for neurodivergent conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Traditionally, diagnosing these disorders can take up to 18 months due to the reliance on subjective assessments, clinical interviews, and behavioral surveys, which often lack standardized biological markers.
A groundbreaking study led by researchers at Indiana University introduces a data-driven approach that leverages AI to identify quantifiable biomarkers and biometric data, significantly reducing diagnostic time to approximately 15 minutes. This innovative method involves analyzing minute movement patterns with sensors attached to participants' hands while performing simple reaching tasks. These sensors capture high-definition kinematic data, including acceleration, rotation, and linear movements, which reveal subtle differences in motor control between neurotypical individuals and those with ASD or ADHD.
The research builds on earlier work from 2018, where the team discovered movement biomarkers imperceptible to the naked eye but measurable with sensors. Using advanced deep learning algorithms, they assessed movement irregularities that correlate with the severity of neurodivergent disorders. This approach offers a new set of objective biomarkers, enabling clinicians to evaluate how serious a condition is and monitor treatment effectiveness.
While the AI-powered diagnostics are designed to augment, not replace, professional clinical assessments, they could serve as valuable tools for early screening and triage in educational and clinical settings. For example, schools could utilize this technology to identify students who may need further evaluation and intervention, facilitating earlier support and care.
The development of these quantitative tools aims to provide a more standardized and reliable method for diagnosing autism and ADHD, ultimately leading to more personalized and effective treatments. By quantifying movement irregularities and employing deep learning, healthcare providers can better understand the severity of neurodivergent conditions and tailor interventions accordingly.
For more details, refer to the original study published in Scientific Reports: Khoshrav P. Doctor et al, Deep learning diagnosis plus kinematic severity assessments of neurodivergent disorders, 2025.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Heavy Menstrual Bleeding: A Common yet Often Overlooked Health Issue
Heavy menstrual bleeding affects millions of women, yet remains poorly understood and undertreated. Innovative organ-on-a-chip technology aims to revolutionize diagnosis and treatment, reducing delays from years to months.
New Overdose Prediction Tool for Cocaine Users Developed by Researchers
Researchers at the University of Pennsylvania have developed an accurate and transparent overdose prediction tool for stimulant users, aiming to enable early interventions and save lives. This innovative model leverages demographic and health data to identify high-risk individuals before overdoses occur.
Blocking Minor Splicing: A Promising Approach to Hindering Tumor Growth Across Multiple Cancer Types
Australian researchers have identified a new approach to slow down tumor growth across multiple cancers by inhibiting minor splicing. This strategy activates cancer cell death pathways while largely sparing healthy cells, offering a promising avenue for broad-spectrum cancer treatment.
Could Psilocybin Be a New Hope for Treating IBS? Insights from Recent Research
Exploring the potential of psilocybin, the active ingredient in magic mushrooms, as a groundbreaking therapy for irritable bowel syndrome (IBS) in recent clinical studies.



